1. Introduction {#sec1}
===============

The past few decades have witnessed a marked increasing prevalence of type 2 diabetes, especially in China, and the global prevalence of microvascular and macrovascular complications associated with diabetes increases dramatically \[[@B1], [@B2]\]. Diabetic nephropathy (DN) has become the leading cause of end-stage kidney disease (ESKD) worldwide \[[@B3], [@B4]\]. The utilization of renin-angiotensin-aldosterone system blockers and improvements in glycemic, blood pressure, and lipid control slow the progression of chronic kidney disease (CKD) to a degree \[[@B5]\]. Indeed, glomerular filtration rate (GFR) guides the clinical management of CKD and is an independent predictor of kidney injury, all-cause/cardiovascular mortality, and kidney failure \[[@B6]\]. Therefore, accurate estimation of GFR to identify CKD and predict kidney outcome is highlighted.

The Kidney Disease Improving Global Outcomes (KDIGO) 2012 Clinical Practice Guideline for the Evaluation and Management of CKD \[[@B7]\] recommends initial use of 2009 CKD-Epidemiology Collaboration equation based on serum creatinine (eGFR~CKD-EPI-Cr~) instead of the Modification of Diet in Renal Disease equation. They also suggest use of the 2012 CKD-EPI equations (eGFR~CKD-EPI-CysC~, eGFR~CKD-EPI-Cr-CysC~) to confirm kidney function when cystatin C has been measured, particularly for patients with eGFR~Cr~ of 45--59 mL/min/1.73 m^2^ who do not have markers of kidney damage. However, the performance of various equations in CKD cohorts remains controversial due to serum creatinine is influenced by age, muscle mass, sex, and race; cystatin C level is affected by ages, body mass index, diabetes, and inflammation. Patients with DN are recognized as a special community in CKD. Also, the implications and predictive potential of different equations in patients with DN have yet to be elucidated. The objective of the study was to compare the performance for detecting kidney injury of equations of eGFR~CKD-EPI-Cr~, eGFR~CKD-EPI-CysC~, and eGFR~CKD-EPI-Cr-CysC~ in patients with DN in a single center in Southwest China.

2. Method {#sec2}
=========

2.1. Study Population {#sec2.1}
---------------------

This is a retrospective cohort study. From November 2003 to March 2018, a total of 308 Chinese patients with type 2 diabetes mellitus (T2DM) and biopsy-proven DN in West China Hospital of Sichuan University were recruited and followed up for at least one year by routine clinical visits. Patients with T2DM and proteinuria \> 0.5 g/24 h or eGFR decline were indicated to receive kidney biopsy in our hospital. The diagnoses of T2DM and DN were based upon the criteria recommended by the American Diabetes Association (ADA) in 2018 \[[@B8]\] and the Renal Pathology Society in 2010 \[[@B9]\]. The ESKD was defined by initiation of renal replacement therapy (hemodialysis, peritoneal dialysis, or kidney transplantation). Patients who had malignances, nondiabetic renal disease (NDRD), and NDRD+DN were excluded from the study.

The protocol of study was approved by the ethics committee of West China Hospital of Sichuan University and conducted based on the principles of the Declaration of Helsinki; written informed consents were obtained at the time of biopsy from all the patients.

2.2. Clinical and Pathological Characteristics {#sec2.2}
----------------------------------------------

Diabetic history, data including physical examinations (body mass index, blood pressure, and examination of diabetic retinopathy) and laboratory tests (HbA1c, 24-hour protein excretion, serum creatinine, serum cystatin C, serum lipid), were collected at the time of kidney biopsy from the hospital information system. Creatinine was measured using Jaffe\'s assay. Serum creatinine value was calibrated to isotope dilution mass spectrometry (IDMS). Serum cystatin C was measured using an automated particle-enhanced immunoturbidimetric method. Blood samples were collected after 12 hours of fasting in all the patients \[[@B10]\]. Pathological lesions were routinely assessed under light and electron microscopy by at least two nephropathologists according to criteria proposed by the Renal Pathology Society in 2010 \[[@B9]\].

2.3. Statistical Analysis {#sec2.3}
-------------------------

GFR was estimated using the equations \[[@B11]\] of eGFR~CKD-EPI-Cr~, eGFR~CKD-EPI-CysC~, and eGFR~CKD-EPI-Cr-CysC~, respectively. The CKD stages 1, 2, 3a, 3b, 4, and 5 were categorized by eGFR (≥90, 60-90, 45-60, 30-45, 15-30, ≤15 mL/min/1.73 m^2^) \[[@B12]\]. The term "reduced kidney function" indicated eGFR \< 60 mL/min/1.73 m^2^. The bias (mean difference) between each two equations was assessed by Bland-Altman plots. The differences in variables were analyzed appropriately by Student\'s *t*-test, the Mann-Whitney test, or the chi-square test. Kidney outcomes were compared using the log-rank test and demonstrated by the Kaplan-Meier curves method. The association between variables was analyzed by multivariable logistic regression. All analyses were conducted using SPSS software 22.0 and GraphPad Prism 7.0, and a two-sided *P* value of less than 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Baseline Demographic Clinical and Pathological Characteristics {#sec3.1}
-------------------------------------------------------------------

A total of 308 patients with biopsy-proven DN were enrolled in the current study ([Table 1](#tab1){ref-type="table"}). Among them, 69.5% of patients were male and the mean age was 51.4 ± 9.7 years old. The mean duration of diabetes was 97.8 ± 70.3 months. 44.8% and 86.0% of patients have diabetic retinopathy and hypertension, respectively. The mean serum creatinine and cystatin C were 130 ± 65 *μ*mol/L and 1.61 ± 0.60 mg/L, respectively. The median (interquartile range) initial proteinuria was 4.3 (2.0-7.8) g/24 hours. The thyroid levels were in normal range. The mean GFR was higher when estimated using the CKD-EPI-Cr (62.6 ± 28.7 mL/min/1.73 m^2^) than using CKD-EPI-CysC (50.3 ± 23.3 mL/min/1.73 m^2^) and CKD-EPI-Cr-CysC (54.6 ± 24.9 mL/min/1.73 m^2^). 81.5% of patients received RAAS inhibitors, 72.1% of patients received insulin therapy, and 57.5% of patients received statins.

All the patients in the study underwent kidney biopsy. Glomerular lesions were classified as follows. Seventeen patients had glomerular basement membrane thickening only and were classified as class I. 104 patients had mild or severe mesangial expansion, but without nodular sclerosis (Kimmelstiel-Wilson lesion), and were classified as class II. 140 patients who did not meet the criteria of class IV with at least one convincing Kimmelstiel-Wilson lesion were classified as class III. 47 patients with global glomerular sclerosis in ≥50% of glomeruli were classified as class IV. For the IFTA score, 10, 138, 127, and 33 patients were scored as 0, 1, 2, and 3, respectively. For interstitial inflammation, 20, 233, and 50 patients were scored as 0, 1, and 2, respectively. For arteriolar hyalinosis, 34, 162, and 112 patients were scored as 0, 1, and 2, respectively.

During a median follow-up period of 20 (13-33) months, a total of 131 (42.5%) patients reached ESKD.

3.2. CKD Stages Categorized Using Different Equations {#sec3.2}
-----------------------------------------------------

[Figure 1](#fig1){ref-type="fig"} shows the proportion of CKD stages categorized using the different equations. Overall, more patients tend to be categorized into advanced CKD stages by eGFR~CKD-EPI-CysC~ and eGFR~CKD-EPI-Cr-CysC~ compared with eGFR~CKD-EPI-Cr~. Approximately half of patients (47%) were included in CKD 1 and CKD 2 stages when using equation of eGFR~CKD-EPI-Cr~, but only 30% of patients in CKD 1 and 2 stages when using equation of eGFR~CKD-EPI-CysC~. On the contrary, 62 patients were categorized into CKD 3b stage and 39 patients were in CKD 4 stage when using eGFR~CKD-EPI-Cr~, but 89 and 58 patients were in CKD 3b and 4 stages, respectively, when using eGFR~CKD-EPI-CysC~.

The Bland-Altman plot shown in [Figure 2](#fig2){ref-type="fig"} revealed the bias between each two equations. Overall, high disconcordance was observed between eGFR~CKD-EPI-Cr~ and eGFR~CKD-EPI-CysC~, especially when eGFR ≥ 60 mL/min/1.73 m^2^. The mean bias of eGFR~CKD-EPI-Cr~ and eGFR~CKD-EPI-CysC~ was 12.28 ± 13.7 mL/min/1.73 m^2^, and upper 95% limit of agreement was 39.13 mL/min/1.73 m^2^, which were beyond accepted limit. The mean bias of eGFR~CKD-EPI-Cr~ and eGFR~CKD-EPI-Cr-CysC~ was 7.98 ± 8.32 mL/min/1.73 m^2^, and the mean bias of eGFR~CKD-EPI-Cr-CysC~ and eGFR~CKD-EPI-CysC~ was 4.29 ± 5.64 mL/min/1.73 m^2^.

3.3. Reclassification to Reduced Kidney Function by eGFR~CKD-EPI-CysC~ Equation {#sec3.3}
-------------------------------------------------------------------------------

A total of 145 patients were with eGFR \> 60 mL/min/1.73 m^2^ (CKD 1 and 2 stages) when using eGFR~CKD-EPI-Cr~ equation; however, 57 of them were reclassified into CKD 3-5 stages when using eGFR~CKD-EPI-CysC~ equation ([Table 2](#tab2){ref-type="table"}). Compared with patients who were not reclassified (*n* = 88), the reclassified group presented significantly longer diabetic duration (106.8 ± 64.8 vs 83.4 ± 61.6 months), heavier proteinuria \[4.2 (2.3-8.8) vs 2.4 (0.8-4.8) g/24 h, *P* = 0.001\], higher level of cystatin C (1.45 ± 0.20 vs 1.02 ± 0.15 mg/L, *P* \< 0.001), lower free triiodothyronine 3 \[3.92 (3.46-4.35) vs 4.41 (3.92-5.10) pmol/L, *P* = 0.003\], advanced glomerular classifications (*P* \< 0.001), IFTA scores (*P* \< 0.001), and interstitial inflammation (*P* \< 0.001). In addition, during the follow-up, 11 (12.5%) patients reached the end point in the not reclassified group, while 21 (36.8%) patients reached the end point in the reclassified group; the kidney survival was significantly poorer by the log-rank test in the reclassified group ([Figure 3(a)](#fig3){ref-type="fig"}). Similarly, 26 patients were reclassified into CKD 3-5 stages using eGFR~CKD-EPI-Cr-CysC~ equation from patients with eGFR~CKD−EPI−Cr~ \> 60 mL/min/1.73 m^2^. A significantly poorer kidney outcome was observed in patients who were reclassified by eGFR~CKD-EPI-Cr-CysC~ during the follow-up period ([Figure 3(b)](#fig3){ref-type="fig"}).

3.4. The Association between Serum Creatinine and Cystatin C and Pathological Lesions {#sec3.4}
-------------------------------------------------------------------------------------

We then investigated the association between serum creatinine and cystatin C and pathological lesions. For glomerular classification, we defined class of III and IV as advanced lesion, and for tubular and interstitial lesions, we defined scores of 2 and 3 of IFTA as advanced lesions. We adjusted essential clinical variables including gender, age, blood pressure, diabetic duration, triglyceride, total cholesterol, and proteinuria for multivariable logistic regression. As shown in [Table 3](#tab3){ref-type="table"}, only gender (odds ratio (OR) 0.349, 95% confidence interval (CI) 0.174-0.700, *P* = 0.003) and cystatin C (OR 3.771, 95% CI 1.140-12.472, *P* = 0.030) were independently associated with advanced glomerular lesions. Serum creatinine (OR 1.004, 95% CI 0.993-1.015, *P* \> 0.05) was not independently associated with advanced glomerular lesions. However, total cholesterol (OR 1.249, 95% CI 1.009-1.545, *P* = 0.041) and serum creatinine (OR 1.012, 95% CI 1.002-1.023, *P* = 0.024) were independently associated with advanced tubular and interstitial injury.

4. Discussion {#sec4}
=============

Despite decades of research and heavy public health burden associated with DN, few new biomarkers have been applied to clinical practice in recent years \[[@B13]\]. Albuminuria and eGFR are still essential ones to monitor kidney function and guide management for patients with DN. However, the performance of GFR estimated by different equations is still under debate \[[@B14]--[@B16]\]. The current study showed the distribution of CKD stages categorized by different equations in patients with kidney-biopsy DN. 39% of patients with CKD 1 and 2 stages (by eGFR~CKD-EPI-Cr~) were reclassified into advanced CKD stages (by eGFR~CKD-EPI-CysC~) and they had longer diabetic duration, heavier proteinuria, advanced pathological lesions, and poorer prognosis. In addition, cystatin C, not creatinine, was independently associated with more severe glomerular classifications. Those findings suggest that equations incorporate cystatin C would improve the performance of detect glomerular lesions in the early stage in patients with DN.

Both serum creatinine and cystatin C are endogenous molecules. Serum creatinine is unstable and easily influenced by daily diet \[[@B10]\], secretion and reabsorption of tubular cells \[[@B17]\], and reduced muscle mass \[[@B18]\] which is common in patients with CKD \[[@B19]\]. Cystatin C is a low molecular basic protein, which is reabsorbed and catabolized by tubular cells completely. The serum concentrate is mainly affected by gender, obesity, diabetes, and hypertension \[[@B20], [@B21]\]. Criteria for selecting the optimal GFR estimating equation are accuracy, discrimination of kidney outcomes \[[@B22]\], and the population characteristic. Recently, substantial studies have evaluated the performance of different eGFR equations in the population of diabetes, CKD, or CKD with diabetes, but the conclusions remain largely controversial.

In the U.S. population of noninstitutionalized civilian, the prevalence of reduced kidney function was 6.5% when estimated using equations based on creatinine, compared with 8.7% when incorporated with cystatin C \[[@B23]\]. Similarly, a study enrolled 778 persons with diabetes detected the prevalence of reduced kidney function was 16.5% and 22.0% using eGFR~Cr~ and eGFR~CysC~, respectively. And patients with diabetes were more likely to be reclassified from preserved kidney function calculated by eGFR~Cr~ to reduced kidney function calculated by eGFR~CysC~ \[[@B20]\]. However, a study included 199 diabetic patients demonstrated that both eGFR~MDRD~ and eGFR~CKD-EPI-Cr~ equations underestimated measured GFR (\>90 mL/min/1.73 m^2^) \[[@B24]\]. Moreover, long-term GFR decline was proved to be largely underestimated in a cross-sectional and longitudinal analysis \[[@B21]\]. In the current study, a biopsy-proven DN cohort, 53% of patients were with reduced kidney function using eGFR~CKD-EPI-Cr~ while 70% of which using eGFR~CKD-EPI-CysC~. Interestingly, patients who were reclassified by eGFR~CKD-EPI-CysC~ have significantly heavier proteinuria, advanced pathological lesions, and faster progression of kidney disease than not reclassified patients, which suggested that eGFR~CKD-EPI-CysC~ was more sensitive to detect kidney injury and predict kidney outcomes.

However, several studies questioned the improved performance of equations based on cystatin C. A latest study with 882 patients reported the misclassification was approximately 50% for creatinine-based equations and still 35% for cystatin C-based equations, and equations combined creatinine and cystatin C were not outperform equation only based on cystatin C \[[@B14]\]. In addition, eGFR~CysC~ failed to improve the area under the curve for the diagnosis of reduced kidney function in patients with diabetes \[[@B25]\]. In the current study, we found that cystatin C, not the creatinine, was independently associated with advanced glomerular lesions. The contradictory can be explained by the characteristics of subjects partially. First, different equations were compared in CKD cohorts which include various primary or secondary kidney diseases. Cystatin C may be influenced by different disease status; even in CKD with diabetes cohort, the nondiabetic kidney disease may confound results \[[@B26], [@B27]\]. Second, subjects in previous studies were characteristic with obese (BMI 28-31 kg/m^2^) and older (\>55 years old). Higher BMI is associated with increased fat mass which is a primary determinant of cystatin C generation \[[@B26]\]. And the accurate of cystatin C is decreased with age \[[@B28]\]. In the current study, the impact of age (51 years old) and BMI (25.78 kg/m^2^) on the performance of eGFR~CysC~ is limited. Third, we aimed to explore the performance of equations to detect kidney injury, not the accuracy in estimating measured GFR.

These findings suggest that eGFR~CysC~ is more sensitive to detect kidney injury in the early stage. Therefore, eGFR~CysC~ should be considered, rather than eGFR~Cr~ alone, for clinical decision-making, especially when eGFR~Cr~ \> 60 mL/min/1.73 m^2^.

There are several limitations of the current study that should be discussed. First, the sample size was limited due to that we only enrolled patients with biopsy-proven DN. Second, all the patients were ethnic Han in Southwest China; the performance of equations may be influenced by multiethnic setting such as muscle mass and meat intake. The results should be verified in more ethnic cohorts. Third, it was a retrospective cohort study; we did not have data of measured GFR to evaluate accuracy of different equations. Fourth, creatinine and cystatin C could be fluctuated; repeated measurements should be applied.

5. Conclusion {#sec5}
=============

eGFR equations incorporating cystatin C is superior to eGFR based on creatine alone for detecting kidney injury in the early stage. The independent association between cystatin C and glomerular classifications might contribute to it.
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![CKD stages categorized using different equations eGFR (mL/min/1.73m^2^). CKD stage 1: eGFR ≥ 90 mL/min/1.73m^2^; CKD stage 2: eGFR (60-90) mL/min/1.73m^2^; CKD stage 3a: eGFR (45-60) mL/min/1.73m^2^; CKD stage 3b: eGFR (30-45) mL/min/1.73m^2^; CKD stage 4: eGFR (15-30) mL/min/1.73m^2^; CKD stage 5: eGFR \< 15 mL/min/1.73m^2^. More patients tend to be categorized into advanced CKD stages by eGFRCKD-EPI-CysC and eGFRCKD-EPI-Cr-CysC compared with eGFRCKD-EPI-Cr.](DM2019-4354061.001){#fig1}

![Bland-Altman plots of the difference between eGFRs. The limits of agreement (LoA) are defined as the mean difference ± 1.96 SD of differences. The black line and the blue lines indicate mean difference and 95% LoA, respectively. The red dashed lines indicate when average eGFR are 60 and 90 mL/min/1.73 m^2^. High disconcordance was observed between eGFR~CKD-EPI-Cr~ and eGFR~CKD-EPI-CysC~, especially when eGFR \> 60 mL/min/1.73 m^2^. SD: standard deviation.](DM2019-4354061.002){#fig2}

![Kidney survival of patients reclassified in advanced CKD stages (3-5) by equations based on cystatin C. Comparison of kidney survival between the not reclassified group and reclassified group by eGFR~CKD-EPI-CysC~ (a) and eGFR~CKD-EPI-Cr-CysC~ (b). The kidney survival was significantly poorer by the log-rank test in the reclassified groups.](DM2019-4354061.003){#fig3}

###### 

Baseline demographic, clinical, and pathological characteristics.

  Variables                                   Patients (*n* = 308)
  ------------------------------------------- ---------------------------------
  Age (years)                                 51.4 ± 9.7
  Gender (male)                               214 (69.5)
  Duration of diabetes (months)               97.8 ± 70.3
  Diabetic retinopathy (%)                    138 (44.8)
  Body mass index (kg/m^2^)                   25.78 ± 3.78
  Hypertension (%)                            265 (86.0)
  Systolic blood pressure (mmHg)              145 ± 23
  Diastolic blood pressure (mmHg)             86 ± 13
  HbA1C (%)                                   7.3 (6.3-8.5)
  Initial proteinuria (g/24 h)                4.3 (2.0-7.8)
  Serum creatinine (*μ*mol/L)                 130 ± 65
  Cystatin C (mg/L)                           1.61 ± 0.60
  Triglyceride (mmol/L)                       2.19 ± 1.80
  Total cholesterol (mmol/L)                  5.22 ± 1.60
  Thyroid-stimulating hormone (mU/L)          3.15 (1.96-5.60) (*n* = 155)
  Free triiodothyronine 3 (pmol/L)            3.92 (3.39-4.41) (*n* = 151)
  Free triiodothyronine 4 (pmol/L)            14.95 (13.17-16.61) (*n* = 154)
  eGFR~CKD-EPI-Cr~                            62.6 ± 28.7
  eGFR~CKD-EPI-CysC~                          50.3 ± 23.3
  eGFR~CKD-EPI-Cr-CysC~                       54.6 ± 24.9
  RAAS inhibitors (%)                         251 (81.5)
  Insulin therapy (%)                         222 (72.1)
  Statins (%)                                 177 (57.5)
  Glomerular class                            
  I                                           17
  IIa                                         75
  IIb                                         29
  III                                         140
  IV                                          47
  Interstitial fibrosis and tubular atrophy   
  0                                           10
  1                                           138
  2                                           127
  3                                           33
  Interstitial inflammation                   
  0                                           20
  1                                           233
  2                                           55
  Arteriolar hyalinosis                       
  0                                           34
  1                                           162
  2                                           112
  Reach end-stage kidney disease              131
  Median kidney survival time (months)        20 (13-33)

Data are presented as the mean ± standard and the median with range or counts and percentages.

###### 

Clinical and pathological characteristics of the not/reclassified group.

  ------------------------------------------------------------------------------------------------------------------
  Variables                            Not reclassified group\          Reclassified group\              *P* value
                                       (*n* = 88)                       (*n* = 57)                       
  ------------------------------------ -------------------------------- -------------------------------- -----------
  eGFR~CKD-EPI-Cr~                     96.5 ± 17.0                      76.1 ± 11.5                      \<0.001

  eGFR~CKD-EPI-CysC~                   79.9 ± 17.1                      49.3 ± 7.2                       \<0.001

  Age (years)                          49.4 ± 10.8                      51.3 ± 8.7                       NS

  Gender (male) (%)                    62 (70.5)                        38 (66.7)                        NS

  Duration of diabetes (months)        83.4 ± 61.6                      106.8 ± 64.8                     0.033

  Diabetic retinopathy (%)             28 (32.6)                        22 (40.0)                        NS

  Body mass index (kg/m^2^)            26.24 ± 3.35                     25.67 ± 4.59                     NS

  Systolic blood pressure (mmHg)       138 ± 20                         144 ± 22                         NS

  Diastolic blood pressure (mmHg)      86 ± 14                          85 ± 13                          NS

  HbA1C (%)                            7.8 (6.8-9.4)                    7.5 (6.3-10.2)                   NS

  Initial proteinuria (g/24 h)         2.4 (0.8-4.8)                    4.2 (2.3-8.8)                    0.001

  Serum creatinine (*μ*mol/L)          74 ± 18                          93 ± 19                          \<0.001

  Cystatin C (mg/L)                    1.02 ± 0.15                      1.45 ± 0.20                      \<0.001

  Triglyceride (mmol/L)                2.39 ± 2.17                      2.03 ± 1.61                      NS

  Total cholesterol (mmol/L)           4.89 ± 1.36                      5.36 ± 1.61                      NS

  Thyroid-stimulating hormone (mU/L)   2.93 (1.79-4.09) (*n* = 43)      3.86 (2.61-6.58) (*n* = 29)      NS

  Free triiodothyronine 3 (pmol/L)     4.41 (3.92-5.10) (*n* = 42)      3.92 (3.46-4.35) (*n* = 29)      0.003

  Free triiodothyronine 4 (pmol/L)     15.87 (14.65-17.26) (*n* = 42)   14.54 (12.50-16.66) (*n* = 29)   NS

                                                                                                         

  Pathological lesions                                                                                   

  Glomerular classification            \<0.001                                                           

  I                                    14                               1                                

  IIa                                  39                               14                               

  IIb                                  6                                7                                

  III                                  26                               29                               

  IV                                   3                                6                                

  IFTA scores                          \<0.001                                                           

  0                                    8                                2                                

  1                                    62                               27                               

  2                                    18                               25                               

  3                                    0                                3                                

  Interstitial inflammation                                             \<0.001                          

  0                                    17                               2                                

  1                                    70                               45                               

  2                                    1                                10                               

  Arteriolar hyalinosis                NS                                                                

  0                                    18                               10                               

  1                                    47                               28                               

  2                                    23                               19                               

  Follow-up period (months)            32 ± 22                          30 ± 18                          NS

  Progressed to ESKD (%)               11 (12.5)                        21 (36.8)                        \<0.001
  ------------------------------------------------------------------------------------------------------------------

Patients in the reclassified group had significantly longer diabetic duration, heavier proteinuria, and advanced pathological lesions. Data are presented as the mean ± standard and the median with range or counts and percentages. IFTA: interstitial fibrosis and tubular atrophy; NS: not significant. A two-tailed *P* \< 0.05 was considered statistically significant.

###### 

Multivariable logistic regression of advanced glomerular classification and IFTA.

  Variables                  Glomerular classification of III and IV   IFTA of 2 and 3 scores                                 
  -------------------------- ----------------------------------------- ------------------------ ------- ------- ------------- -------
  Gender (male)              0.349                                     0.174-0.700              0.003   1.037   0.538-2.000   NS
  Age                        0.985                                     0.955-1.015              NS      0.985   0.956-1.015   NS
  Systolic blood pressure    1.008                                     0.991-1.025              NS      1.004   0.988-1.020   NS
  Diastolic blood pressure   0.995                                     0.966-1.025              NS      1.015   0.987-1.043   NS
  Diabetic duration          1.003                                     0.999-1.008              NS      1.001   0.997-1.005   NS
  Triglyceride               0.905                                     0.769-1.063              NS      0.941   0.803-1.104   NS
  Total cholesterol          1.022                                     0.821-1.271              NS      1.249   1.009-1.545   0.041
  Proteinuria                1.059                                     0.979-1.146              NS      1.018   0.949-1.092   NS
  Serum creatinine           1.004                                     0.993-1.015              NS      1.012   1.002-1.023   0.024
  Cystatin C                 3.771                                     1.140-12.472             0.030   1.680   0.576-4.902   NS

Gender and cystatin C were independently associated with advanced glomerular classifications (III and IV stages); total cholesterol and serum creatinine were independently associated with higher IFTA scores. IFTA: interstitial fibrosis and tubular atrophy; CI: confidence interval; NS: not significant. A two-tailed *P* \< 0.05 was considered statistically significant.
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